Speranza Therapeutics Launches New Division to Help Pharma Manufacturers Adapt to Market Shifts

Speranza Therapeutics launches Lotus Therapeutics to address the urgent need for agile generic pharmaceutical commercialization, supporting manufacturers navigating complex reimbursement changes and prioritizing US-based manufacturing.

BOCA RATON, Fla., April 23, 2025 /PRNewswire/ -- Speranza Therapeutics, a recognized leader in neuromodulation therapies for addiction and pain management associated with opioid detox , today announced the launch of Lotus Therapeutics , a new division focused on commercializing generic pharmaceuticals. This strategic move positions Speranza to support pharmaceutical manufacturers navigating complex state-level reimbursement changes and shifting federal policies.

The formation of Lotus Therapeutics reflects Speranza's commitment to innovation and adaptability in a rapidly changing healthcare environment. With mounting regulatory pressures—such as the removal of the Medicaid AMP Cap, waste penalties, and changes to Best Price rules—many drug manufacturers are re-evaluating how their branded and authorized generic (AG) products are positioned and reimbursed in the marketplace.

Additionally, recent years have seen growing momentum—spurred in part by initiatives from the Trump administration—toward reshoring pharmaceutical manufacturing and strengthening US domestic supply chains. These trends have intensified the need for nimble, U.S.-based commercial partners like Lotus Therapeutics that can help bring high-quality generic alternatives to market swiftly and compliantly.

"We launched Lotus Therapeutics to meet an urgent and growing need in the pharmaceutical industry," said Sal J. Rafanelli, RPh, CEO of Speranza Therapeutics. "As reimbursement frameworks shift and U.S.-based manufacturing becomes increasingly prioritized, manufacturers require agile, strategic partners who understand both the regulatory landscape and how to drive commercial success. Lotus brings that capability to the table."

Lotus Therapeutics will focus on:

• Complex generics approaching loss of exclusivity (LOE)
• 505(b)(2) and ANDA/NDA development and commercialization opportunities
• Strategic partnerships with manufacturers seeking market access and channel optimization under new reimbursement models

The division is already in advanced discussions with several leading pharmaceutical companies exploring co-commercialization and licensing partnerships to optimize go-to-market strategies in light of recent policy shifts.

Speranza Therapeutics is well known for its innovative, patient-first solutions in medical devices and drug detox. With the formation of Lotus, the company extends its operational agility and commercial acumen into the generics space—guided by a leadership team with decades of experience across the branded, generic, and specialty pharmaceutical sectors.

To learn more, visit http://www.lotusthera.com/.

About Speranza Therapeutics

Speranza Therapeutics is a medical device and pharmaceutical company that is dedicated to making meaningful, more efficient and cost-effective changes in delivering medical devices and drugs to patients in the United States. Their success is the collective result of visionary leaders and dedicated clinicians focused on disrupting the norm, improving care, and making an important difference in the lives of patients with complex medical conditions. Their guiding principle is simple: to remove the inherent challenges in delivering treatment to patients in need through proven, clinically effective therapeutics and technology.

For more information, contact our Marketing Manager Lauren Saccone, [email protected]

SOURCE Speranza Therapeutics